Heron Therapeutics, Inc. provided sales guidance for the first quarter of 2022. The company currently expects the first quarter of 2022 net product sales for the oncology care franchise in the range of $20 million to $22 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.47 USD | -0.86% | +9.12% | +104.12% |
06-24 | Heron Therapeutics, Inc.(NasdaqCM:HRTX) added to S&P Biotechnology Select Industry Index | CI |
06-12 | Connect Biopharma Names New Chief Executive, Chair | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+104.12% | 527M | |
+16.59% | 45.51B | |
-9.89% | 38.52B | |
+38.08% | 38.13B | |
+27.12% | 30.74B | |
-8.64% | 26.03B | |
+11.81% | 25.92B | |
+45.08% | 14.13B | |
+32.85% | 12.73B | |
-7.19% | 11.29B |
- Stock Market
- Equities
- HRTX Stock
- News Heron Therapeutics, Inc.
- Heron Therapeutics, Inc. Provides Sales Guidance for the First Quarter of 2022